Kenneth M. Boucher, PhD

Research Interests

  • Biostatistics
  • Mathematical Modeling
  • Topology
  • Statistical Consulting
  • Grant Writing

Labs

Lab Website

Languages

  • English

Academic Information

  • Departments: Internal Medicine - Research Associate Professor
  • Divisions: Biostatistics, Epidemiology
  • Cancer Center Programs: Cancer Control & Population Sciences

Academic Office Information

  • 801-585-9544
  • Huntsman Cancer Institute
    2000 Circle of Hope, Room: 4245
    Salt Lake City, UT 84112

Academic Bio

Dr. Kenneth Boucher is Co-Director of the Cancer Biostatistics Unit of the Study Design and Biostatistics Center at the University of Utah Health Sciences Center. He is a Research Associate Professor in the Department of Internal Medicine and Adjunct Associate Professor in the Department of Family and Preventive Medicine. He has been at the University of Utah since 1990 and at the Huntsman Cancer Institute since 1996. He is a member of the Cancer Control and Population Sciences Program at HCI.

Dr. Boucher has numerous research interests in the fields of cancer biostatistics and mathematical modeling. These interests include analysis of microarray data, high throughput genomics, carcinogenesis modeling, and cancer epidemiology.

Education History

Type School Degree
Doctoral Training University of Michigan
Mathematics
Ph.D.
Graduate Training University of Notre Dame
Mathematics
M.S.
Undergraduate Washington University
Mathematics
B.S.

Selected Publications

Journal Article

  1. Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Invest New Drugs, 37(3), 482-489.
  2. Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen SL (2019). AKT1E17K activates focal adhesion kinase and promotes melanoma brain metastasis. (Epub ahead of print) Mol Cancer Res.
  3. Stewart RL, Updike KL, Factor RE, Henry NL, Boucher KM, Bernard PS, Varley KE (2019 May 2). A multigene assay determines risk of recurrence in patients with triple-negative breast cancer.LID - canres.3014.2018 [pii]LID - 10.1158/0008-5472.CAN-18-3014 [doi]. (Epub ahead of print) Cancer Res.
  4. Wu YP, Parsons BG, Aspinwall LG, Hay JL, Boucher KM, Caputo H, Mooney R, Grossman D, Leachman SA (2019 Mar 20). Parent and child perspectives on perceived barriers to child sun protection and their association with sun protection strategies among children of melanoma survivors. Pediatr Dermatol, 36(3), 317-323.
  5. Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, OHare T, Deininger MW (2019 Apr 1). Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin Cancer Res, 25(7), 2323-2335.
  6. Samadder NJ, Neklason D, Snow A, Samowitz W, Cessna MH, Rowe K, Sandhu I, Boucher K, Pappas L, Smith KR, Wong J, Curtin K, Provenzale D, Burt RW (2019 Mar 29). Clinical and Molecular Features of Post-Colonoscopy Colorectal Cancers.LID - S1542-3565(19)30246-0 [pii]LID - 10.1016/j.cgh.2019.02.040 [doi]. (Epub ahead of print) Clin Gastroenterol Hepatol.
  7. Kanth P, Hazel MW, Boucher KM, Yang Z, Wang L, Bronner MP, Boylan KE, Burt RW, Westover M, Neklason DW, Delker DA (2019 Jan). Small RNA sequencing of sessile serrated polyps identifies microRNA profile associated with colon cancer. Genes Chromosomes Cancer, 58(1), 23-33.
  8. Ulrich CM, Himbert C, Boucher K, Wetter DW, Hess R, Kim J, Lundberg K, Ligibel JA, Barnes CA, Rushton B, Marcus R, Finlayson SRG, LaStayo PC, Varghese TK (2018 Dec 16). Precision-Exercise-Prescription in patients with lung cancer undergoing surgery: rationale and design of the PEP study trial. BMJ Open, 8(12), e024672.
  9. Drost M, Tiersma Y, Thompson BA, Frederiksen JH, Keijzers G, Glubb D, Kathe S, Osinga J, Westers H, Pappas L, Boucher KM, Molenkamp S, Zonneveld JB, van Asperen CJ, Goldgar DE, Wallace SS, Sijmons RH, Spurdle AB, Rasmussen LJ, Greenblatt MS, de Wind N, Tavtigian SV (2018 Dec 3). A functional assay-based procedure to classify mismatch repair gene variants in Lynch syndrome.LID - 10.1038/s41436-018-0372-2 [doi]. (Epub ahead of print) Genet Med.
  10. Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, Agarwal N (2018 Dec). Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. Oncologist, 23(12), 1413-e151.
  11. Samadder NJ, Valentine JF, Guthery S, Singh H, Bernstein CN, Leighton JA, Wan Y, Wong J, Boucher K, Pappas L, Rowe K, Burt RW, Curtin K, Smith KR (2018 Sep 26). Family History Associates With Increased Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.LID - S1542-3565(18)31029-2 [pii]LID - 10.1016/j.cgh.2018.09.038 [doi]. (Epub ahead of print) Clin Gastroenterol Hepatol.
  12. Tavtigian SV, Greenblatt MS, Harrison SM, Nussbaum RL, Prabhu SA, Boucher KM, Biesecker LG (2018 Sep). Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med, 20(9), 1054-1060.
  13. Sample DC, Samadder NJ, Pappas LM, Boucher KM, Samowitz WS, Berry T, Westover M, Nathan D, Kanth P, Byrne KR, Burt RW, Neklason DW (2018 Jul 16). Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients. BMC Gastroenterol, 18(1), 115.
  14. Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL (2018 Jun). p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 21(2), 260-268.
  15. Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P (2018 May 15). Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 124(10), 2115-2124.
  16. Samadder NJ, Kuwada SK, Boucher KM, Byrne K, Kanth P, Samowitz W, Jones D, Tavtigian SV, Westover M, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Burt RW, Neklason DW (2018 May 1). Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol, 4(5), 671-677.
  17. Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ (2018 Apr). Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clin Genitourin Cancer, 16(2), e373-e382.
  18. Wu YP, Nagelhout E, Aspinwall LG, Boucher KM, Parsons BG, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Leachman SA (2018 Mar). A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Patient Educ Couns, 101(3), 452-459.
  19. Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ (2018 Feb 27). Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. Blood Adv, 2(4), 381-389.
  20. Ou JY, Fowler B, Ding Q, Kirchhoff AC, Pappas L, Boucher K, Akerley W, Wu Y, Kaphingst K, Harding G, Kepka D (2018 Jan 31). A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population. BMC Cancer, 18(1), 115.
  21. Delker DA, Wood AC, Snow AK, Samadder NJ, Samowitz WS, Affolter KE, Boucher KM, Pappas LM, Stijleman IJ, Kanth P, Byrne KR, Burt RW, Bernard PS, Neklason DW (2018 Jan). Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia. Cancer Prev Res (Phila), 11(1), 4-15.
  22. Samadder NJ, Smith KR, Wong J, Thomas A, Hanson H, Boucher K, Kopituch C, Cannon-Albright LA, Burt RW, Curtin K (2017 Dec 1). Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome. JAMA Oncol, 3(12), 1697-1701.
  23. Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (2017 Oct). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res, 27(5), 477-484.
  24. Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N (2017 Sep 6). Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer.LID - S1558-7673(17)30272-0 [pii]LID - 10.1016/j.clgc.2017.08.017 [doi]. (Epub ahead of print) Clin Genitourin Cancer.
  25. Samadder NJ, Pappas L, Boucher KM, Smith KR, Hanson H, Fraser A, Wan Y, Burt RW, Curtin K (). Long-Term Colorectal Cancer Incidence After Negative Colonoscopy in the State of Utah: The Effect of Family History. Am J Gastroenterol, 112(9), 1439-1447.
  26. Jewel Samadder N, Valentine JF, Guthery S, Singh H, Bernstein CN, Wan Y, Wong J, Boucher K, Pappas L, Rowe K, Bronner M, Ulrich CM, Burt RW, Curtin K, Smith KR (2017 Aug). Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah. Dig Dis Sci, 62(8), 2126-2132.
  27. Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N (2017 Aug). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clin Genitourin Cancer, 15(4), e599-e602.
  28. Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ (2017 Jul). Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Surgery, 162(1), 104-111.
  29. Huang WC, Ferris E, Cheng T, Horndli CS, Gleason K, Tamminga C, Wagner JD, Boucher KM, Christian JL, Gregg C (2017 Mar 8). Diverse Non-genetic, Allele-Specific Expression Effects Shape Genetic Architecture at the Cellular Level in the Mammalian Brain. Neuron, 93(5), 1094-1109.e7.
  30. Cohen AL, Factor RE, Mooney K, Salama ME, Wade M, Serpico V, Ostrander E, Nelson E, Porretta J, Matsen C, Bernard P, Boucher K, Neumayer L (2017 Feb). POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast, 31, 219-223.
  31. Mendenhall SD, Anderson LA, Ying J, Boucher KM, Neumayer LA, Agarwal JP (2017 Jan). The BREASTrial Stage II: ADM Breast Reconstruction Outcomes from Definitive Reconstruction to 3 Months Postoperative. Plast Reconstr Surg Glob Open, 5(1), e1209.
  32. Cassidy PB, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman D (2017 Jan). A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila), 10(1), 36-44.
  33. Agarwal S, Ying J, Boucher KM, Agarwal JP (2017). The association between socioeconomic factors and breast cancer-specific survival varies by race. PLoS ONE, 12(12), e0187018.
  34. Hashibe M, Abdelaziz S, Al-Temimi M, Fraser A, Boucher KM, Smith K, Lee YA, Rowe K, Rowley B, Daurelle M, Holton AE, VanDerslice J, Richiardi L, Bishoff J, Lowrance W, Stroup A (2016 Dec). Long-term health effects among testicular cancer survivors. J Cancer Surviv, 10(6), 1051-1057.
  35. Samadder NJ, Smith KR, Wong J, Hanson H, Boucher K, Burt RW, Charlton M, Byrne KR, Gallegos-Orozco JF, Koptiuch C, Curtin K (2016 Dec). Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah. Dig Dis Sci, 61(12), 3627-3632.
  36. Kepka D, Ding Q, Hawkins AJ, Warner EL, Boucher KM (2016 Dec). Factors associated with early adoption of the HPV vaccine in US male adolescents include Hispanic ethnicity and receipt of other vaccines. Prev Med Rep, 4, 98-102.
  37. Truong A, Strazzulla L, March J, Boucher KM, Nelson KC, Kim CC, Grossman D (2016 Jul). Reduction in nevus biopsies in patients monitored by total body photography. J Am Acad Dermatol, 75(1), 135-143.e5.
  38. Kanth P, Bronner MP, Boucher KM, Burt RW, Neklason DW, Hagedorn CH, Delker DA (2016 Jun). Gene Signature in Sessile Serrated Polyps Identifies Colon Cancer Subtype. Cancer Prev Res (Phila), 9(6), 456-65.
  39. Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, Sharma S (2016 Apr). Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Invest New Drugs, 34(2), 243-52.
  40. Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Akerley W, Gilcrease G, Ulrich CM, Burt RW, Curtin K (2016 Mar). Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA Oncol, 2(3), 340-6.
  41. Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK (2016 Mar 22-29). Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA, 315(12), 1266-75.
  42. Serpico V, Liepert AE, Boucher K, Fouts DL, Anderson L, Pell J, Neumayer L (2016 Mar). The Effect of Previsit Education in Breast Cancer Patients: A Study of a Shared-decision-making Tool. Am Surg, 82(3), 259-65.
  43. Samadder NJ, Curtin K, Pappas L, Boucher K, Mineau GP, Smith K, Fraser A, Wan Y, Provenzale D, Kinney AY, Ulrich C, Burt RW (2016 Feb). Risk of Incident Colorectal Cancer and Death After Colonoscopy: A Population-based Study in Utah. Clin Gastroenterol Hepatol, 14(2), 279-86.e1-2.
  44. Smits-Seemann RR, Kaul S, Hersh AO, Fluchel MN, Boucher KM, Kirchhoff AC, Smits-Seemann RR, Kaul S, Hersh AO, Fluchel MN, Boucher KM, Kirchhoff AC (2016 Feb). ReCAP: Gaps in Insurance Coverage for Pediatric Patients With Acute Lymphoblastic Leukemia. J Oncol Pract, 12(2), 175-6; e207-14.
  45. Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Ahnen D, Singh H, Ulrich CM, Burt RW, Curtin K (2015 Dec). Increased Risk of Colorectal Cancer Among Family Members of All Ages, Regardless of Age of Index Case at Diagnosis. Clin Gastroenterol Hepatol, 13(13), 2305-11.e1-2.
  46. Werner TL, Wade ML, Agarwal N, Boucher K, Patel J, Luebke A, Sharma S (2015 Dec). A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-beta, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Invest New Drugs, 33(6), 1217-24.
  47. Kaul S, Kirchhoff AC, Boucher KM, Dietz AC (2015 Dec). Conditional survival for pediatric and adolescent patients with cancer: Implications for survivorship care. Cancer Epidemiol, 39(6), 1071-7.
  48. Mendenhall SD, Anderson LA, Ying J, Boucher KM, Neumayer LA, Agarwal JP (2015). The BREASTrial Stage II: ADM Breast Reconstruction Outcomes from the Time of Implant Exchange to 3 Months Post-Op. Plast Reconstr Surg, 136(4 Suppl), 111-2.
  49. Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM (2015 Sep 3). FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging, 15(1), 15.
  50. Steffen LE, Boucher KM, Damron BH, Pappas LM, Walters ST, Flores KG, Boonyasiriwat W, Vernon SW, Stroup AM, Schwartz MD, Edwards SL, Kohlmann WK, Lowery JT, Wiggins CL, Hill DA, Higginbotham JC, Burt R, Simmons RG, Kinney AY (2015 Sep). Efficacy of a Telehealth Intervention on Colonoscopy Uptake When Cost Is a Barrier: The Family CARE Cluster Randomized Controlled Trial. Cancer Epidemiol Biomarkers Prev, 24(9), 1311-8.
  51. Rudrapatna VK, Morley K, Boucher KM, Pierson AS, Shull CT, Kushner JP, Shami PJ (2015 Aug). Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy. Leuk Res, 39(8), 835-9.
  52. Chen LA, Anker CJ, Hunt JP, Buchmann LO, Grossmann KF, Boucher K, Fang LM, Shrieve DC, Hitchcock YJ (2015 May). Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience. Cancer Med, 4(5), 651-60.
  53. Anker CJ, Hymas RV, Ahluwalia R, Kokeny KE, Avizonis V, Boucher KM, Neumayer LA, Agarwal JP (2015 May-Jun). The Effect of Radiation on Complication Rates and Patient Satisfaction in Breast Reconstruction using Temporary Tissue Expanders and Permanent Implants. Breast J, 21(3), 233-40.
  54. Kaur I, Kosak KM, Terrazas M, Herron JN, Kern SE, Boucher KM, Shami PJ (2015 Apr). Effect of a Pluronic((R)) P123 formulation on the nitric oxide-generating drug JS-K. Pharm Res, 32(4), 1395-406.
  55. Samadder NJ, Smith KR, Mineau GP, Pimentel R, Wong J, Boucher K, Pappas L, Singh H, Ahnen D, Burt RW, Curtin K (2015 Mar). Familial colorectal cancer risk by subsite of primary cancer: a population-based study in Utah. Aliment Pharmacol Ther, 41(6), 573-80.
  56. Campo RA, Light KC, OConnor K, Nakamura Y, Lipschitz D, LaStayo PC, Pappas LM, Boucher KM, Irwin MR, Hill HR, Martins TB, Agarwal N, Kinney AY (2015 Mar). Blood pressure, salivary cortisol, and inflammatory cytokine outcomes in senior female cancer survivors enrolled in a tai chi chih randomized controlled trial. J Cancer Surviv, 9(1), 115-25.
  57. Chen LA, Kim J, Boucher K, Terakedis B, Williams B, Nickman NA, Gaffney DK (2015 Mar). Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers. Gynecol Oncol, 136(3), 521-8.
  58. Mendenhall SD, Anderson LA, Ying J, Boucher KM, Liu T, Neumayer LA, Agarwal JP (2015 Jan). The BREASTrial: stage I. Outcomes from the time of tissue expander and acellular dermal matrix placement to definitive reconstruction. Plast Reconstr Surg, 135(1), 29e-42e.
  59. Agarwal JP, Mendenhall SD, Anderson LA, Ying J, Boucher KM, Liu T, Neumayer LA (2015 Jan). The breast reconstruction evaluation of acellular dermal matrix as a sling trial (BREASTrial): design and methods of a prospective randomized trial. Plast Reconstr Surg, 135(1), 20e-8e.
  60. Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt RW (2014 Dec). Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah. Clin Gastroenterol Hepatol, 12(12), 2078-84.e1-2.
  61. Kinney AY, Butler KM, Schwartz MD, Mandelblatt JS, Boucher KM, Pappas LM, Gammon A, Kohlmann W, Edwards SL, Stroup AM, Buys SS, Flores KG, Campo RA (2014 Dec). Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.LID - 10.1093/jnci/dju328 [doi]LID - dju328 [pii]. J Natl Cancer Inst, 106(12).
  62. Samadder NJ, Curtin K, Tuohy TM, Rowe KG, Mineau GP, Smith KR, Pimentel R, Wong J, Boucher K, Burt RW (2014 Oct). Increased risk of colorectal neoplasia among family members of patients with colorectal cancer: a population-based study in Utah. Gastroenterology, 147(4), 814-821.e5; quiz e15-6.
  63. El-Chaar NN, Piccolo SR, Boucher KM, Cohen AL, Chang JT, Moos PJ, Bild AH (2014 Oct). Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. Mol Oncol, 8(7), 1339-54.
  64. Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD (2014 Sep). Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol, 9(3), 195-204.
  65. Firpo MA, Boucher KM, Mulvihill SJ (2014 Aug 5). Prospects for developing an accurate diagnostic biomarker panel for low prevalence cancers. Theor Biol Med Model, 11(1), 34.
  66. Kendrick ZW, Firpo MA, Repko RC, Scaife CL, Adler DG, Boucher KM, Mulvihill SJ (2014 Jul). Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. HPB (Oxford), 16(7), 670-6.
  67. Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G (2014 Apr). Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 12(2), 130-7.
  68. Samadder NJ, Curtin K, Tuohy TM, Pappas L, Boucher K, Provenzale D, Rowe KG, Mineau GP, Smith K, Pimentel R, Kirchhoff AC, Burt RW (2014 Apr). Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. Gastroenterology, 146(4), 950-60.
  69. Campo RA, Agarwal N, LaStayo PC, OConnor K, Pappas L, Boucher KM, Gardner J, Smith S, Light KC, Kinney AY (2014 Mar). Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. J Cancer Surviv, 8(1), 60-9.
  70. Terakedis BE, Anker CJ, Leachman SA, Andtbacka RH, Bowen GM, Sause WT, Grossmann KF, Bowles TL, Noyes RD, Hitchcock YJ, Boucher KM, Shrieve DC (2014 Mar). Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp. J Am Acad Dermatol, 70(3), 435-42.
  71. Kinney AY, Boonyasiriwat W, Walters ST, Pappas LM, Stroup AM, Schwartz MD, Edwards SL, Rogers A, Kohlmann WK, Boucher KM, Vernon SW, Simmons RG, Lowery JT, Flores K, Wiggins CL, Hill DA, Burt RW, Williams MS, Higginbotham JC (2014 Mar 1). Telehealth personalized cancer risk communication to motivate colonoscopy in relatives of patients with colorectal cancer: the family CARE Randomized controlled trial. J Clin Oncol, 32(7), 654-62.
  72. Mendenhall SD, Anderson LA, Ying J, Boucher KM, Neumayer LA, Agarwal JP (2014 Mar). Abstract 6: The BREASTrial: Breast Reconstruction Evaluation of Acellular Dermal Matrix as a Sling Trial, Design and Stage I Outcomes of a Randomized Trial. Plast Reconstr Surg, 133(3 Suppl), 13-4.
  73. Tanner P, Leachman S, Boucher K, Ozcelik TB (2014 Feb). Depigmented skin and phantom color measurements for realistic prostheses. Skin Res Tech, 20(1), 37-42.
  74. Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD (2014 Feb). Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev, 40(1), 190-6.
  75. Terakedis BE, Jensen RL, Boucher K, Shrieve DC (2014). Tumor control and incidence of radiation necrosis after reirradiation with stereotactic radiosurgery for brain metastases. J Radiosurg SBRT, 3(1), 21-28.
  76. Anderson AE, Flores KG, Boonyasiriwat W, Gammon A, Kohlmann W, Birmingham WC, Schwartz MD, Samadder J, Boucher K, Kinney AY (2014). Interest and informational preferences regarding genomic testing for modest increases in colorectal cancer risk. Public Health Genomics, 17(1), 48-60.
  77. Warner EL, Fluchel M, Wright J, Sweeney C, Boucher KM, Fraser A, Smith KR, Stroup AM, Kinney AY, Kirchhoff AC (2014). A population-based study of childhood cancer survivors' body mass index. J Cancer Epidemiol, 2014, 531958.
  78. Ghia AJ, Tward JD, Anker CJ, Boucher KM, Jensen RL, Shrieve DC (2014). Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control. J Radiosurg SBRT, 3(1), 43-50.
  79. Quackenbush JF, Cassidy PB, Pfeffer LM, Boucher KM, Hawkes JE, Pfeffer SR, Kopelovich L, Leachman SA (2014). Isolation of circulating microRNAs from microvesicles found in human plasma. Methods Mol Biol, 1102, 641-53.
  80. Anker CJ, ODonnell K, Boucher KM, Gaffney DK (2013 Winter). Effect of brachytherapy technique and patient characteristics on cervical cancer implant dosimetry. Med Dosim, 38(4), 430-5.
  81. Campo RA, OConnor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, Pappas L, Boucher K, Irwin MR, Agarwal N, Kinney AY (2013 Nov). Feasibility and acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors. Integrative Cancer Therapies, 12(6), 464-74.
  82. Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S (2013 Oct). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs, 31(5), 1257-64.
  83. Super N, Tieman J, Boucher K, Rockwell WB, Agarwal JP (2013 Oct). Recent trends in applicants and the matching process for the integrated plastic surgery match. Ann Plast Surg, 71(4), 406-9.
  84. Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami PJ (2013 Sep). Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles. J Pharm Pharmacol, 65(9), 1329-36.
  85. Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (2013 Sep). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 11(3), 316-20.
  86. Greene T, Joffe M, Hu B, Li L, Boucher K (2013 May 7). The balanced survivor average causal effect. Int J Biostat, 9(2), 291-306.
  87. Horvath LE, Werner T, Boucher K, Jones K (2013 May). The relationship between tumor size and stage in early versus advanced ovarian cancer. Med Hypotheses, 80(5), 684-7.
  88. Cassidy PB, Fain HD, Cassidy JP Jr, Tran SM, Moos PJ, Boucher KM, Gerads R, Florell SR, Grossman D, Leachman SA (2013 Mar 7). Selenium for the prevention of cutaneous melanoma. Nutrients, 5(3), 725-49.
  89. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ (2013 Mar). The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med, 13(3), 340-51.
  90. Akerley W, Boucher K, Rich N, Egbert L, Harker G, Bylund J, Van Duren T, Reddy C (2013 Mar). A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 79(3), 307-11.
  91. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ (2013 Mar). Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas, 42(2), 193-7.
  92. Ying J, Sivendran S, Agarwal N, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD (2013). Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: A systematic review and meta-analysis. J Clin Oncol, 31(6_suppl), 362.
  93. Ying J, Gartrell BA, Agarwal N, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD (2013). Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis. J Clin Oncol, 31(6_suppl), 398.
  94. Thompson BA, Greenblatt MS, Vallee MP, Herkert JC, Tessereau C, Young EL, Adzhubey IA, Li B, Bell R, Feng B, Mooney SD, Radivojac P, Sunyaev SR, Frebourg T, Hofstra RM, Sijmons RH, Boucher K, Thomas A, Goldgar DE, Spurdle AB, Tavtigian SV (2013 Jan). Calibration of multiple in silico tools for predicting pathogenicity of mismatch repair gene missense substitutions. Hum Mutat, 34(1), 255-65.
  95. Rondina MT, Lam UT, Pendleton RC, Kraiss LW, Wanner N, Zimmerman GA, Hoffman JM, Hanrahan C, Boucher K, Christian PE, Butterfield RI, Morton KA (2012 Dec). (18)F-FDG PET in the evaluation of acuity of deep vein thrombosis. Clin Nucl Med, 37(12), 1139-45.
  96. Bastien RR, Rodriguez-Lescure A, Ebbert MT, Prat A, Munarriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Alvarez I, Dowell T, Wall D, Segui MA, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Anton A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martin M (2012 Oct 4). PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics, 5(1), 44.
  97. Enslow MS, Zollinger LV, Morton KA, Butterfield RI, Kadrmas DJ, Christian PE, Boucher KM, Heilbrun ME, Jensen RL, Hoffman JM (2012 Sep). Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma. Clin Nucl Med, 37(9), 854-61.
  98. Jahromi MS, Putnam AR, Druzgal C, Wright J, Spraker-Perlman H, Kinsey M, Zhou H, Boucher KM, Randall RL, Jones KB, Lucas D, Rosenberg A, Thomas D, Lessnick SL, Schiffman JD (2012 Jul-Aug). Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma. Cancer Genet, 205(7-8), 391-404.
  99. Beck R, Monument MJ, Watkins WS, Smith R, Boucher KM, Schiffman JD, Jorde LB, Randall RL, Lessnick SL (2012 Jun). EWS/FLI-responsive GGAA microsatellites exhibit polymorphic differences between European and African populations. Cancer Genet, 205(6), 304-12.
  100. Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T (2012 Apr). Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl, 18(4), 423-33.
  101. Agarwal N, Boucher KM, Maughan B, Hussain SA, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (2012). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC). J Clin Oncol, 30(5_suppl), 308.
  102. Agarwal N, Boucher KM, Maughan B, Hussain SA, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (2012). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC). J Clin Oncol, 30(5_suppl), 308.
  103. Liu J, Welm B, Boucher KM, Ebbert MT, Bernard PS (2012 Feb). TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer. Am J Pathol, 180(2), 839-47.
  104. Bowen AR, Burt L, Boucher K, Tristani-Firouzi P, Florell SR (2012 Feb). Use of proliferation rate, p53 staining and perforating elastic fibers in distinguishing keratoacanthoma from hypertrophic lichen planus: a pilot study. J Cutan Pathol, 39(2), 243-50.
  105. Kelly CM, Bernard PS, Krishnamurthy S, Wang B, Ebbert MT, Bastien RR, Boucher KM, Young E, Iwamoto T, Pusztai L (2012). Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX(R)) and the PAM50 breast cancer intrinsic Classifier in early-stage estrogen receptor-positive breast cancer. Oncologist, 17(4), 492-8.
  106. Kerber RA, OBrien E, Boucher KM, Smith KR, Cawthon RM (2012). A genome-wide study replicates linkage of 3p22-24 to extreme longevity in humans and identifies possible additional loci. PLoS ONE, 7(4), e34746.
  107. Ebbert MT, Bastien RR, Boucher KM, Martin M, Carrasco E, Caballero R, Stijleman IJ, Bernard PS, Facelli JC (2011 Dec 23). Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans. J Clin Bioinforma, 1(1), 37.
  108. Gammon AD, Rothwell E, Simmons R, Lowery JT, Ballinger L, Hill DA, Boucher KM, Kinney AY (2011 Dec). Awareness and preferences regarding BRCA1/2 genetic counseling and testing among Latinas and non-Latina white women at increased risk for hereditary breast and ovarian cancer. J Genet Couns, 20(6), 625-38.
  109. Goodson AG, Florell SR, Boucher KM, Grossman D (2011 Nov). A decade of melanomas: identification of factors associated with delayed detection in an academic group practice. Dermatol Surg, 37(11), 1620-30.
  110. Zangari M, Berno T, Zhan F, Boucher KM, Tricot G, Fink L (2011 Jul). Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagul Fibrinolysis, 22(5), 420-3.
  111. Bastien RR, Ebbert MT, Boucher KM, Kelly CM, Wang B, Iwamoto T, Krishnamurthy S, Pusztai L, Bernard PS (2011). Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: A direct comparison to Oncotype DX. J Clin Oncol, 29(15_suppl), 503.
  112. Ebbert MT, Bastien RR, Rowe LR, Miller PA, Anderson D, Boucher KM, Pappas LM, Fauron C, Lyons BW, Dowell T, Wall DE, Barley L, Bernard PS (2011). PAM50 breast cancer intrinsic classifier: Clinical validation of a multianalyte laboratory developed test. J Clin Oncol, 29(15_suppl), 10597.
  113. Fukuda A, Wang SC, Morris JP 4th, Folias AE, Liou A, Kim GE, Akira S, Boucher KM, Firpo MA, Mulvihill SJ, Hebrok M (2011 Apr 12). Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell, 19(4), 441-55.
  114. Jenkins NC, Liu T, Cassidy P, Leachman SA, Boucher KM, Goodson AG, Samadashwily G, Grossman D (2011 Jan 20). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene, 30(3), 265-74.
  115. Demarest BL, Horsley WH, Locke EE, Boucher K, Grunwald DJ, Trede NS (2011 Jan). Trans-centromere effects on meiotic recombination in the zebrafish. Genetics, 187(1), 333-6.
  116. Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ (2010 Oct). Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 19(10), 2605-10.
  117. Anker CJ, Hymas RV, Hazard LJ, Boucher KM, Jensen RL, Shrieve DC (2010 Jun). Stereotactic radiosurgery eligibility and selection bias in the treatment of glioblastoma multiforme. J Neurooncol, 98(2), 253-63.
  118. Scaife CL, Shea J, Emerson L, Boucher K, Firpo MA, Beckerle MC, Mulvihill SJ (2010 Jun). Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma. HPB (Oxford), 12(5), 352-8.
  119. Goodson AG, Florell SR, Boucher KM, Grossman D (2010 Apr). Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi. J Am Acad Dermatol, 62(4), 591-6.
  120. Anker CJ, Cachoeira CV, Boucher KM, Rankin J, Gaffney DK (2010 Mar 1). Does the entire uterus need to be treated in cancer of the cervix? Role of adaptive brachytherapy. Int J Radiat Oncol Biol Phys, 76(3), 704-12.
  121. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL (2010 Feb). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 18(2), 442-6.
  122. Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ (2010 Jan). JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J Pharm Pharmacol, 62(1), 145-51.
  123. Goodson AG, Cotter MA, Cassidy P, Wade M, Florell SR, Liu T, Boucher KM, Grossman D (2009 Dec 1). Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention. Clin Cancer Res, 15(23), 7434-40.
  124. Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N (2009). A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol, 147(5), 691-9.
  125. Luo W, Gangwal K, Sankar S, Boucher KM, Thomas D, Lessnick SL (2009 Nov 19). GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance. Oncogene, 28(46), 4126-32.
  126. Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N (2009). A Phase I/II study of the safety and efficacy of the addition of sirolimus to tactrlimus/methotrexate graft versus host disease prophylaxis after allogeneic heamatopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol, 147(5), 691-9.
  127. Pulsipher MA, Boucher KM, Wall D, Frangoul H, Duval M, Goyal RK, Shaw PJ, Haight AE, Grimley M, Grupp SA, Kletzel M, Kadota R (2009 Aug 13). Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood, 114(7), 1429-36.
  128. Slattery ML, Curtin K, Wolff RK, Boucher KM, Sweeney C, Edwards S, Caan BJ, Samowitz W (2009 Jul). A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum, 52(7), 1304-11.
  129. Hazard LJ, Shrieve DC, Sklow B, Pappas L, Boucher KM (2009 May). Local Excision vs. Radical Resection in T1-2 Rectal Carcinoma: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data. Gastrointest Cancer Res, 3(3), 105-14.
  130. Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ (2009 Apr). Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg, 33(4), 716-22.
  131. Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T (2009 Feb). A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol, 4(2), 214-9.
  132. Sweeney C, Boucher KM, Samowitz WS, Wolff RK, Albertsen H, Curtin K, Caan BJ, Slattery ML (2009 Jan). Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes Chromosomes Cancer, 48(1), 1-9.
  133. Nix DA, Courdy SJ, Boucher KM (2008 Dec 5). Empirical methods for controlling false positives and estimating confidence in ChIP-Seq peaks. BMC Bioinformatics, 9(1), 523.
  134. Samlowski WE, Majer M, Boucher KM, Shrieve AF, Dechet C, Jensen RL, Shrieve DC (2008 Nov 1). Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer, 113(9), 2539-48.
  135. Florell SR, Smoller BR, Boucher KM, Grossman D, Harris RM, Bowen GM, Leachman SA (2008 Nov). Sampling of melanocytic nevi for research purposes: a prospective, pilot study to determine effect on diagnosis. J Am Acad Dermatol, 59(5), 814-21.
  136. Neklason DW, Thorpe BL, Ferrandez A, Tumbapura A, Boucher K, Garibotti G, Kerber RA, Solomon CH, Samowitz WS, Fang JC, Mineau GP, Leppert MF, Burt RW, Kuwada SK (2008 Oct). Colonic adenoma risk in familial colorectal cancer--a study of six extended kindreds. Am J Gastroenterol, 103(10), 2577-84.
  137. Florell SR, Meyer LJ, Boucher KM, Grossman D, Cannon-Albright LA, Harris RM, Samlowski WE, Zone JJ, Leachman SA (2008 Aug). Increased melanocytic nevi and nevus density in a G-34T CDKN2A/p16 melanoma-prone pedigree. J Invest Dermatol, 128(8), 2122-5.
  138. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ, Lessnick SL (2008 Jul 22). Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci U S A, 105(29), 10149-54.
  139. Neklason DW, Stevens J, Boucher KM, Kerber RA, Matsunami N, Barlow J, Mineau G, Leppert MF, Burt RW (2008 Jan). American founder mutation for attenuated familial adenomatous polyposis. Clin Gastroenterol Hepatol, 6(1), 46-52.
  140. Majer M, Jensen RL, Shrieve DC, Watson GA, Wang M, Leachman SA, Boucher KM, Samlowski WE (2007 Sep 15). Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer, 110(6), 1329-37.
  141. OBrien E, Kerber R, Smith K, Mineau G, Boucher K, Reed DL (2007 Aug). Familial mortality in the Utah population database: characterizing a human aging phenotype. J Gerontol A Biol Sci Med Sci, 62(8), 803-12.
  142. Samlowski WE, Watson GA, Wang M, Rao G, Klimo P Jr, Boucher K, Shrieve DC, Jensen RL (2007 May 1). Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer, 109(9), 1855-62.
  143. Wendland MM, Smith DC, Boucher KM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK (2007 Apr). The impact of involved field radiation therapy in the treatment of relapsed or refractory non-Hodgkin lymphoma with high-dose chemotherapy followed by hematopoietic progenitor cell transplant. Am J Clin Oncol, 30(2), 156-62.
  144. Dabrowski M, Boucher K, Ward JH, Lovell MM, Sandre A, Bloch J, Carlquist L, Porter M, Norman L, Buys SS (2007 Jan). Clinical experience with the NCCN distress thermometer in breast cancer patients. J Natl Compr Canc Netw, 5(1), 104-11.
  145. Braunreiter CL, Hancock JD, Coffin CM, Boucher KM, Lessnick SL (2006 Dec). Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma. Cell Cycle, 5(23), 2753-9.
  146. Garibotti G, Smith KR, Kerber RA, Boucher KM (2006 Dec). Longevity and correlated frailty in multigenerational families. J Gerontol A Biol Sci Med Sci, 61(12), 1253-61.
  147. Florell SR, Cessna M, Lundell RB, Boucher KM, Bowen GM, Harris RM, Petersen MJ, Zone JJ, Tripp S, Perkins SL (2006 May). Usefulness (or lack thereof) of immunophenotyping in atypical cutaneous T-cell infiltrates. Am J Clin Pathol, 125(5), 727-36.
  148. Lewis TB, Robison JE, Bastien R, Milash B, Boucher K, Samlowski WE, Leachman SA, Dirk Noyes R, Wittwer CT, Perreard L, Bernard PS (2005 Oct 15). Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer, 104(8), 1678-86.
  149. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski WE, Leachman SA (2005 Oct 1). Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol, 23(28), 7168-77.
  150. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR (2005 Jun 10). Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol, 23(17), 3897-905.
  151. Wheeler RH, Jones D, Sharma P, Davis RK, Spilker H, Boucher K, Leachman S, Grossman D, Salzman K, Akerley W (2005). Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). J Clin Oncol, 23(16_suppl), 5531.
  152. Zhang W, Hanks AN, Boucher K, Florell SR, Allen SM, Alexander A, Brash DE, Grossman D (2005 Jan). UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis, 26(1), 249-57.
  153. Shrieve DC, Hazard L, Boucher K, Jensen RL (2004 Nov). Dose fractionation in stereotactic radiotherapy for parasellar meningiomas: radiobiological considerations of efficacy and optic nerve tolerance. J Neurosurg, 101 Suppl 3, 390-5.
  154. Call TR, Boucher KM, Whiting BL, Hart M, Newman K, Kinney AY, Bowen GM, Zone JJ, Branson D, Leachman SA (2004 Oct). Motivating factors for attendance of skin cancer screenings. J Am Acad Dermatol, 51(4), 642-4.
  155. Florell SR, Meyer LJ, Boucher KM, Porter-Gill PA, Hart M, Erickson J, Cannon-Albright LA, Pershing LK, Harris RM, Samlowski WE, Zone JJ, Leachman SA (2004 Sep). Longitudinal assessment of the nevus phenotype in a melanoma kindred. J Invest Dermatol, 123(3), 576-82.
  156. Florell SR, Schmidt SJ, Porter-Gill P, Albertine KH, Murphy KJ, McKinney CB, Boucher KM, Grossman D, Biddle DL, Clayton F, Layfield LJ, Leachman SA (2003 Dec). Novel application of a fibrin cell block method to evaluate melanocytic cell populations. Pigment Cell Res, 16(6), 662-9.
  157. Szabo A, Boucher K, Jones D, Tsodikov AD, Klebanov LB, Yakovlev AY (2003 Oct). Multivariate exploratory tools for microarray data analysis. Biostatistics, 4(4), 555-67.
  158. Florell SR, Boucher KM, Leachman SA, Azmi F, Harris RM, Malone JC, Martignoni G, Bowen GM, Gerwels JW, Hood AF (2003 May). Histopathologic recognition of involved margins of lentigo maligna excised by staged excision: an interobserver comparison study. Arch Dermatol, 139(5), 595-604.
  159. Szabo A, Boucher K (2002 Apr). Estimating an oncogenetic tree when false negatives and positives are present. Math BioSci, 176(2), 219-36.
  160. Szabo A, Boucher K, Carroll WL, Klebanov LB, Tsodikov AD, Yakovlev AY (2002 Mar). Variable selection and pattern recognition with gene expression data generated by the microarray technology. Math BioSci, 176(1), 71-98.
  161. Boucher K, Zorin A, Yakovlev AY, Mayer-Proschel M, Noble M (2001 Jul). An alternative stochastic model of generation of oligodendrocytes in cell culture. J Math Biol, 43(1), 22-36.
  162. Boucher KM, Kerber RA (2001-01-01). The shape of the hazard function for cancer incidence. Math Comput Model, 33, 1361-1376.
  163. Boucher KM, Kerber RA (2001). Measures of familial aggregation as predictors of breast-cancer risk. J Epidemiol Biostat, 6(5), 377-85.
  164. Beatty PG, Boucher KM, Mori M, Milford EL (2000 Aug). Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol, 61(8), 834-40.
  165. Boucher KM, Slattery ML (2000-01-01). Modeling the effects of continuous risk factors: response. J Clin Epidemiol, 53, 220-221.
  166. Slattery ML, Edwards SL, Boucher KM, Anderson K, Caan BJ (1999 Oct 15). Lifestyle and colon cancer: an assessment of factors associated with risk. Am J Epidemiol, 150(8), 869-77.
  167. Hanin LG, Boucher KM (1999 Aug). Identifiability of parameters in the Yakovlev-Polig model of carcinogenesis. Math BioSci, 160(1), 1-24.
  168. Boucher K, Yakovlev AY, Mayer-Proschel M, Noble M (1999 Jun). A stochastic model of temporally regulated generation of oligodendrocytes in cell culture. Math BioSci, 159(1), 47-78.
  169. Yakovlev AY, Tsodikov AD, Boucher K, Kerber R (1999). The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer, 85(8), 1789-98.
  170. Yakovlev A, Boucher K, DiSario J (1999). Modeling insight into spontaneous regression of tumors. Math BioSci, 155(1), 45-60.
  171. Yakovlev A, Tsodikov A, Boucher K, Kerber, R (1999-01-01). The shape of the hazard function in breast cancer: curability of the disease revisited. Cancer, 85, 1789-1798.
  172. Yakovlev A, Boucher K, and DiSario, J (1999-01-01). Modeling insight into spontaneous regression of tumors. Math BioSci, 155, 45-60.
  173. Boucher KM, Slattery ML, Berry TD, Quesenberry C, Anderson K (1998 Dec). Statistical methods in epidemiology: a comparison of statistical methods to analyze dose-response and trend analysis in epidemiologic studies. J Clin Epidemiol, 51(12), 1223-33.
  174. Yakovlev AY, Boucher K, Mayer-Proschel M, Noble M (1998 Nov 24). Quantitative insight into proliferation and differentiation of oligodendrocyte type 2 astrocyte progenitor cells in vitro. Proc Natl Acad Sci U S A, 95(24), 14164-7.
  175. Slattery ML, Boucher KM (1998 Jul 1). The senior authors' response: Factor analysis as a tool for evaluating eating patterns. Am J Epidemiol, 148(1), 20-1.
  176. Slattery ML, Boucher KM, Caan BJ, Potter JD, Ma KN (1998 Jul 1). Eating patterns and risk of colon cancer. Am J Epidemiol, 148(1), 4-16.
  177. Boucher K, Pavlova LV, Yakovlev AY (1998 Jun). A model of multiple tumorigenesis allowing for cell death: quantitative insight into biological effects of urethane. Math BioSci, 150(1), 63-82.
  178. Lillquist DR, Lee JS, Ramsay, JR, Boucher K, Weiss Z and Lyon JL (1998-01-01). A comparison of indoor/outdoor PM10 concentrations measured at three hospitals and a centrally located monitor in Utah. Appl Occup Environ Hyg, 13, 409-415.
  179. Boucher KM, Yakovlev AY (1997 Nov 25). Estimating the probability of initiated cell death before tumor induction. Proc Natl Acad Sci U S A, 94(24), 12776-9.
  180. Mori M, Beatty PG, Graves M, Boucher KM, Milford EL (1997 Oct 15). HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation, 64(7), 1017-27.
  181. Boucher KM, Brown M, and Slaminka E (1993-01-01). A Nielson-type theorem for area-preserving homeomorphisms of the two disc. Lect Notes Pure Appl Math, 149, 43-50.

Review

  1. Hansen CB, Wadge LM, Lowstuter K, Boucher K, Leachman SA (2004 May). Clinical germline genetic testing for melanoma. [Review]. Lancet Oncol, 5(5), 314-9.

Book Chapter

  1. Szabo A, Boucher KM (July 2008). Oncogenetic Trees. In W-Y Tan and L Hanin (Eds.), Handbook of Cancer Models with Applications (pp. 1-24). Singapore: Word Scientific.
  2. Boucher KM, Asselain B, Tsodikov AD, Yakovlev AY (2004). Semiparametric versus parametric regression analysis based on the bounded cumulative hazard model: an application to breast cancer recurrence. In M Nikulin, M Balakrishnan ,M Mesbah and N Limnios (Eds.), Parametric and Semiparametric Models with Applications to Reliability, Survival Analysis, and Quality of Life (pp. 399-415). Boston: Birkhäuser.
  3. Boucher K, Mori M, Milford E, Beatty PG (1998-01-01). Estimation of HLA-A,-B,-DR haplotype frequencies in five racial groups represented in the NMDP donor file. Lenexa, Kansas: American Society for Histocompatibility and Immunogenetics.

Conference Proceedings

  1. McCoy H, Kohlmann W, Neklason DW, Burt RW, Boucher KM (). Descriptive review and comparison of clinical outcomes of AFAP patients. Hereditary Cancer in Clinical Practice, 9(Suppl 1), 25.
  2. Tuohy TM, Neklason DW, Boucher KM, Pimentel RG, Rowe KG, Mineau GP, Burt RW (). Defining the overlap between sporadic and attenuated familial adenoma risk. Hereditary Cancer in Clinical Practice, 9(Suppl 1), 37.
  3. Boucher KM, Lyon JL (1996). Daily mortality and exposure to PM10 air pollution. Proceedings of the Second Colloquium on Particulate Air Pollution and Health, Irvine, CA: University of California, 4-36- 4-54.
  4. Lillquist DR, Rederlechner N, Boucher K (1996). Field evaluation of AIRmetrics MinVol PM10 and PM2.5 samplers. Proceedings of the Second Colloquium on Particulate Air Pollution and Health, Park City UT, Irvine, CA: University of California, 4-263 - 4-270.
  5. Lillquist DR, Rederlacher N, Boucher KM (1996). Relationship among EPA sampling methodologies for PM10 and PM2.5 and there association with meteorological variables (temperature, wind-speed, relative humidity). Proceedings of the Second Colloquium on Particulate Air Pollution and Health, Park City UT, Irvine, CA: University of California, 4-590- 4-613.
  6. Lillquist DR, Lee JS, Ramsay JR, Boucher KM, Weiss Z, Lyon JL (1996). A comparison of indoor/outdoor PM10 concentrations measured at three hospitals and a centrally located monitor in Utah. Proceedings of the Second Colloquium on Particulate Air Pollution and Health, Park City UT, Irvine, CA: University of California, 4-245 - 4-262.

Letter

  1. Florell SR, Meyer LJ, Boucher KM, Hart M, Cannon-Albright LA, Harris RM, Grossman D, Samlowski WE, Zone JJ, Brinton JP, Leachman SA (2005 Dec). Nevus distribution in a Utah melanoma kindred with a temperature-sensitive CDKN2A mutation [Letter to the editor]. J Invest Dermatol, 125(6), 1310-2.
  2. Florell SR, Boucher KM, Holden JA, Meyer LJ, Samlowski WE, Cannon-Albright LA, Zone JJ, Leachman SA (2002 Feb). Failure to detect differences in proliferation status of nevi from CDKN2A mutation carriers and non-carriers [Letter to the editor]. J Invest Dermatol, 118(2), 386-7.

Abstract

  1. Broadbent T, Tantravahi SK, Ravulapati S, Ward M, Asay A, Peddinti A, Kunz I, Shami PJ, Kovacsovic T, Courdy S, Boucher K, Deininger MW ().

    Comorbidities Are Major Drivers of Overall Survival of Chronic Myelomonocytic Leukemia

    [Abstract]. 132(Suppl 1), 5521.
  2. Wu YP, Boucher K, Hay JL, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Zhu A, Grossman D, Mooney K, Leachman SA, Tercyak K (). A family-focused intervention to promote use of sun protection among children of melanoma patients [Abstract]. Annals of Behavioral Medicine, 53 (Suppl 1).
  3. Griswald, CR, Bailey EB, Mauser JC, Boucher KM, Agarwal N, Gupta S, Maughan BL ().

    Risk factors for venous thromboembolism (VTE) during chemotherapy in patients with germ cell tumors (GCT).

    [Abstract]. 37(7_supp;).
  4. Stephens, DM, Boucher K, Kander E, Parikh SA, Parry E, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato AR, Winter AM, Hill BT, Gaballa S, Danilov AV, Philips TJ, Brander DM, Smith SM, Davids MSRogers KA, Glenn M, Byrd JC ().

    Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration

    [Abstract]. 132(Suppl 1), 1648.
  5. Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks J, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C ().

    Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial

    [Abstract]. 23(12), 1413-e151.
  6. Maughan BL, Hahn A, Hoffman J, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Nachaegari G, Nussenzveig R, Boucher K, Agarwal A ().

    825P Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) vs. EZ alone in metastatic castration refractory prostate cancer (mCRPC)

    [Abstract]. 29(suppl_8), mdy284.034.
  7. Kohli DR, Smith Km Wong J, Yu Z, Boucher K, Burt R, Curtin K, Samadder NJ ().

    Familial Pancreatic Cancer Risk by Subsite of Primary Cancer: A Population-Based Study: 4

    [Abstract]. 113, S3-S4.
  8. Wu YP, Parsons BG, Aspinwall LG, Hay JL, Caputo H, Boucher K, Mooney R, Grossman D, Leachman SA (). Barriers to and facilitators of melanoma preventive behaviors predict reported sun protection in children with familial risk [Abstract]. Ann. Behav. Med, 52(Suppl 1), S665.
  9. Wu YP, Nagelhout ES, Aspinwall LG, Boucher KM, Parsons B, Kohlmann W, Kaphingst KA, Lensink R, Homburger S, Perkins RD, Grossman D, Harding G, Leachman SA (). A risk communication and prevention intervention for children at risk for melanoma and their families: Acceptability and preliminary effects on knowledge and sun protection behaviors [Abstract]. Ann. Behav. Med, 52(Suppl 1), S176.
  10. Nagelhout ES, Grahmann-Parsons B, Patil A, Aspinwall L, Boucher KM, Kohlmann W, Kaphingst KA, Homburger S, Perkins RD, Grossman D, Harding G, Leachman SA, Wu YP (). Delivery of Novel Educational Intervention to Increase Knowledge and Perceived Risk for Melanoma among Children with Familial Risk for Melanoma [Abstract]. Annual conference of the American Public Health Association, Atlanta, GA.
  11. Cohen AL, Neumayer L, Factor R, Boucher K, Wade ML, Lamb JG, Arbogast K, Piccolo S, Shreshtha G, Riegert J, Schabel M, Bild AH, Werner TL (). A phase 1 window of opportunity study of valproic acid (VPA) in breast cancer testing a gene expression biomarker [Abstract]. J Clin Oncol, 34, abst 1084.
  12. Samadder NJ, Pappas LM, Boucher KM, Smith K, Hanson H, Fraser A, Wan Y, Ulrich C et al (). Risk of Developing Colorectal Cancer after Negative Colonoscopy in Persons With and Without a Family History of Colon Cancer: A Genealogical Population-Based Study in Utah [Abstract]. Gastroenterology, 150(4), S153.
  13. Anker CV, Bagshaw HP, Sarkar V, Dritto K, Boucher K, Jensen RL, Shrieve DC (). Impact of Subventricular Zone Dose and Relationship to Glioblastoma Tumor Location on Outcomes [Abstract]. International Journal of Radiation Oncology, 93(3), E110-E111.
  14. Garrido-Laguna I, Tometich D, Boucher K, Sharma S (). Abstract B93: A data base of N of 1 case reports from pancreatic cancer patients enrolled in First-in-man studies 2002 through 2012 [Abstract]. Cancer Research, 75(13(Supplement)), B93.
  15. Kamal S, Firpo MA, Scaife CL, Adler GD, Boucher KM Mulvihil SJ (). Abstract B13: Plasma basigin as an early detection marker for pancreatic adenocarcinoma [Abstract]. Cancer Research, 75(13 supplement), B23.
  16. Tibor Kovacsovics, Alice S Mims, Mohamed E Salama, Narayanam Rao, Jeremy Pantin, Michael WN Deininger, Thomas P Kennedy, Linda M Bavisotto, Kenneth M Boucher, Stephen Garrett Marcus, Paul J Shami (). O-desulfated heparin and chemotherapy for the treatment of AML [Abstract]. J. Clin Oncol, 33(suppl; abstr 7053).
  17. Samadder NJ, Curtin K, Pappas L, Boucher KM, Mineau GP, Smith K, Fraser Y et al (). Risk of Developing Colorectal Cancer Following a Negative Colonoscopy: A Population-Based Study in Utah [Abstract]. Gastroenterology, 148(4), S-138.
  18. Samadder NJ, Curtin K, Pappas L, Boucher KM, Provenzale D, Mineau GP, Smith K, Fraser A et al (). Risk of Incident Colorectal Cancer Diagnosis After Colonoscopy: A Population-Based Study in Utah [Abstract]. Gastroenterology, 146(5), S-132-S-133.
  19. Samadder NJ, Curtin K, Tuohy T, Pappas L, Boucher KM, Provenzale D, Rowe K, Mineau GP et al (). Prevalence and Predictors of Missed or Interval Colorectal Cancer: A Population-based Study in Utah [Abstract]. Gastroenterology, 144(5), S-1-S-2.
  20. Gantrell BA, Ying J, Sivendran S, Agarwal N, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD (). Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: A systematic review and meta-analysis [Abstract]. J Clin Oncol 31, 31(suppl 6; abstr 362).
  21. Sivendran S, Ying J, Gantrell A, Agarwal N, Boucher KM, Choueiri, TK, Sonpadve G, Oh WK, Galsky MD (). Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis [Abstract]. J Clin Oncol 31, 2013, 31(suppl 6; abstr 398).
  22. Maughan B, Boucher KM, Agarwal N, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko Y, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Beer TM, Sternberg CN, Rosenberg JE, Bellmunt J, Sonpavde G (). Progression-free survival at 6 months (PFS6) as an endpoint in trials of second-line therapy for advanced urothelial carcinoma (UC [Abstract]. J Clin Oncol, 30; Suppl, abst 4525.
  23. Maugham B, Boucher KM, Agarwal N, et al (). Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC) [Abstract]. J Clin Oncol, 30((suppl; abstr 4525).
  24. Grissom, D, Wade M, Weis JR, Boucher KM Sharma S (). Feasibility analysis of mutational status of advanced colorectal cancer patients and correlation to disease progression [Abstract]. J Clin Oncol, 30(suppl; abstract e 14177).
  25. Agarwal N, Boucher KM, Maugham B, Hussain SA Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC) [Abstract]. J Clin Oncol, 30(suppl 5; abstr 308).
  26. Ebert MTW, Bastien RRL, Rowe LR, Miller Pa, Anderson D, Boucher KM Pappas LM, Fauron B, Lyons BW, Dowell T, Wall DE, Barley L, Bernard PS (). PAM50 breast cancer intrinsic classifier: Clinical validation of a multianalyte laboratory developed test. [Abstract]. J Clin Oncol, 29((suppl; abstr 10597).
  27. Bastien RRL, Ebbert MTW, Boucher KM, Kelly CM, Wang B, Iwamoto T, Krishnamurhty S, Pusztai L, Bernard PS (). Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: A direct comparison to Oncotype DX. [Abstract]. J Clin Oncol, 29(suppl; abstr 503).
  28. Anker CJ, Hymas RV, Ahluwalia R, Agarwal JP, Kokeny KE, Avizonis V, Boucher KM, Neumayer LA (). The Effect of Radiation on Cosmesis and Complication Rates in Breast Reconstruction using Temporary Tissue Expanders and Permanent Implants [Abstract]. American Radium Society.
  29. Firpo MA, Shea JE, Brown K, Emerson LE, Boucher KM, Scaife CL, Mulvihill SJ (). Serum MMP-7 is an Independent Predictor of Survival in Patients with Pancreatic Adenocarcinoma [Abstract]. HPB, 13((Suppl 1), 21.
  30. Berno T, Boucher K, Zhan F, Fink LM, Tricot GJ, Mughal B, Zangari M (). Activated Protein C Resistance (APC-R) Analyzed as a Continuous Variable Is Significantly Decreased In Patients with Multiple Myeloma (MM) Compared to Normal Individuals [Abstract]. Blood (ASH Meeting Abstracts), 116, 4988.
  31. Berno T, Boucher K, Zhan F, Tricot GJ, Mughal B, Zangari M (). Bone Mineral Density Changes In Patients with Paraproteinemia After Treatment with Bortezomib [Abstract]. Blood (ASH Meeting Abstracts), 116, 4989.
  32. Anker CJ, DOnnell KO, Boucher KM, Gaffney DK (). Does Anesthesia during Cervical Cancer Brachytherapy Improve Implant Quality? [Abstract]. International Journal of Radiation Oncology, 78(3), S408-S409.
  33. Montenegro R, Vu N, Jahromi M, Boucher K, Miles RR, Barnette P, Schiffman JD (). Pilot Study of Ethnic Variation in Biological Features of Childhood Acute Lymphoblastic Leukemia (ALL) in Utah [Abstract]. Blood (Ash Annual Meeting Abstracts), 114, 4117.
  34. Samlowki WE, Majer M, Boucher KM, Shrieve AF, Dechet C, Jensen RL, Shrieve D (2009). Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating sterotactic radiosurgery (SRS) [Abstract]. 2009 Genitourinary Cancers Symposium.
  35. Gangwal K, Sankar, S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ, Lessnick SL (2008). Microsatellites as EWS/FLI response elements in Ewing's sarcoma [Abstract]. American Association of Cancer Research Annual Meeting,San Diego, CA. Abstract 86.
  36. Anker, CJ, Cahcoeira CV, Boucher K, Rankin J, Gaffney DK (). Adaptive High Dose Rate Brachytherapy for Carcinoma of the Cervix [Abstract]. Int J Radiat Oncol Biol Phys, 72(1), S367.
  37. Samuelson SJ, Swierczek S, Parker CJ, Jelinek J, Boucher K, Prchal JT (2007). Analysis of mutant cMPL in Philadelphia Chromosome-negative myeloproliferative disorders (PhMPDs) using a novel high-sensitivity assay [Abstract]. American Society of Hematology Annual Meeting.
  38. Leachman S, Boucher K, Cassidy P, Pimentel R, Mineau G, Cannon-Albright L, Florell S, Grossman D, Andtbacka R, Bowen G (December 2007). A Preliminary Study of the Design and Feasibility of Melanoma Prevention Trials [Abstract]. Pigment Cell Research, 20(6), 541.
  39. Phillips JD, Pop I, Boucher K, Y MK (). Up-Regulation of miR-195 Expression Leads to Decreased Expression of Basic Fibroblast Growth Factor in CLL Patients Treated with DNA Methylation Inhibitors [Abstract]. Blood (ASH Annual Meeting Abstracts), 110, 3183.
  40. Condie MW, Boucher KM, Burt RW, Neklason DW (October 2007). Evaluation of ODC1 genotype as a modifier of adenoma number in attenuated FAP [Abstract]. Am J Hum Gen. ASHJ.
  41. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, Shah AA, Boucher KM, Watkins WS, Jorde LB, Graves BJ, Lessnick SL (2007). DNA is an EWS/FLI response element in Ewing's sarcoma [Abstract]. Connective Tissue Oncology Society annual meeting, Seattle, WA. Abstract 790.
  42. Gorman DR, Gangotena F, Boucher K, Wong RF (). Assessment of Risk Factors for Mucinous Pancreatic Cysts [Abstract]. Gastrointest Endpscop, 65(5), AB306.
  43. Wheeler FH, Jones D, Sharma P, Davis RK, Spilker H, Boucher K, Leachman S, Grossman D, Salzman K, Akerley W (2005). Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [Abstract]. 2005 ASCO Annual Meeting Proceedings, 23, 5531.
  44. Wong RF, Omer EN, Kerber RA, Boucher K, DiSaro JA (2005). Analysis of pancreatic tumor types in familial pancreatic cancer [Abstract]. 2005 Gastrointestinal Cancers Symposium .
  45. Florell SF, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski WE, Leachman SA (2004). Prognostic factors and survival in familial melanoma [Abstract]. Melanoma Research Congress, November 2004.
  46. Omer N, Boucher K, DiSario J (). Survival outcomes in familial pancreatic cancer [Abstract]. Pancreas, 29(4), 348.
  47. KLish M, Shrieve DC, Macdonald DM, Boucher KM, Thomson JW, Bruggers CS, Watson GA (). Childhood ependymomas: An analysis of factors impacting survival [Abstract]. Int J RAdiat Oncol Biol Phys, 60(1), S309-S310.
  48. Wong RF, Dalton AL, Barlow J, Erickson J, Boucher K, Burt RW (2004). Relationship of Colon Adenomas to Diet and Exercise in Subjects at High-Risk of Colon Cancer Based on Family History [Abstract]. DDW.
  49. Florell SR, Meyer LJ, Boucher KM, Portergill P, Erickson H, Cannon-Albright L, Harris RM, Samlowski WE, Zone JJ, Leachman SA (2003). Phenotypic observations of a Utah melanoma kindred: fifteen years later [Abstract]. Foundation for melanoma research, Philadelphia.
  50. Boucher KM, Szabo A (2003). Control of the false discovery rate for random search procedures [Abstract]. Eastern North American Region of the International Biometric Society 2003 Spring Meeting, Tampa FL.
  51. 12 Leachman SA, Astle J, Boucher KM, Kerber RA, Mineau G, Wiggins C, Tsodikov A (2002). Prognostic factors and survival in familial melanoma [Abstract]. Society for Investigative Dermatology.
  52. Kerber RA, Boucher KM (Sept 2001). Pseudo-liklihood Estimation of Genetic Parameters for Arbitrarily Complex Pedigrees [Abstract]. 10th Annual Conference, International Genetic Epidemiology Society, Garmisch-Partenkirchen, Germany.
  53. Boucher KM, Kerber RA (2000). The shape of the hazard function for cancer incidence [Abstract]. Proceedings: Era of Hope Department of Defense Breast Cancer Research Program Meeting, Atlanta, GA.
  54. Boucher KM (1998). A stochastic model allowing for competition between tumorigenesis and cell death [Abstract]. 1998 Meeting of the International Biometric Society, ENAR, Pittsburgh, PA.
  55. Milford EL, Mori M, Boucher KM, Beatty P (1997). Polymorphism and disequilibrium of HLA region genes [Abstract]. 1997 Meeting of the American Association of Anthropological Genetics, Mexico City, Mexico.
  56. Mansfield JT, Boucher KM, Lyon JL, Stephenson RA (1997). Prostate needle biopsy Gleason score is a poor predictor of the grade of radical prostatectomy specimens: a population-based study [Abstract]. 1997 meeting of the American Urological Association, New Orleans, LA.
  57. Mori M, Boucher KM (1997). Generalized linear mixed models for informatively censored longitudinal data [Abstract]. 1997 Joint Statistical Meeting, Anaheim, CA.
  58. Milford EL, Mori M, Boucher KM, Beatty P (1997). Racial and geographic heterogeneity of HLA phenotypes and haplotypes in the North American Population [Abstract]. 1997 Meeting of the American Association of Anthropological Genetics, Mexico City, Mexico.

Other

  1. Boucher KM (06/01/1990). Similitudes of surface mapping class groups and reducible outer automorphisms of free groups. University of Michigan Doctoral Dissertation.